Table 3.
Projected US Patent Expirations for Major Biologicals53
| Product | Brand Name | Potential Biosimilar Entry |
|---|---|---|
| Filgrastim | Neupogen | 2013 |
| Epoetin alfa | Epogen/Procrit | 2014 |
| Pegfilgrastim | Neulasta | 2015 |
| Palivizumab | Synagis | 2015 |
| Rituximab | Rituxan | 2016 |
| Cetuximab | Erbitux | 2016 |
| Adalimumab | Humira | 2016 |
| Infliximab | Remicade | 2018 |
| Trastuzumab | Herceptin | 2019 |
| Bevacizumab | Avastin | 2019 |
| Darbepoetin | Aranesp | 2024 |
| Etanercept | Enbrel | 2028 |
This table represents the best available projections. Patent expirations are subject to rapid change, including various legal and regulatory actions. Patent expiration does not guarantee biosimilar availability. .